These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9157077)

  • 1. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.
    Smith RE; Lew D; Rodriguez GI; Taylor SA; Schuller D; Ensley JF
    Invest New Drugs; 1996; 14(4):403-7. PubMed ID: 9157077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
    Murphy BA; Leong T; Burkey B; Langer C; Forastiere A
    Am J Clin Oncol; 2001 Feb; 24(1):64-6. PubMed ID: 11232952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
    Robert F; Soong SJ; Wheeler RH
    Am J Clin Oncol; 1997 Jun; 20(3):298-302. PubMed ID: 9167758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study.
    Kuebler JP; Benedetti J; Schuller DE; Ensley J; Grunberg SM; Muirhead MJ; Richert-Boe KE; Marshall ME
    Invest New Drugs; 1994; 12(4):341-4. PubMed ID: 7775138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA; Cmelak A; Burkey B; Netterville J; Shyr Y; Douglas S; Smith W
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
    Duffaud F; Borner M; Chollet P; Vermorken JB; Bloch J; Degardin M; Rolland F; Dittrich C; Baron B; Lacombe D; Fumoleau P;
    Eur J Cancer; 2004 Dec; 40(18):2748-52. PubMed ID: 15571957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
    Perez-Soler R; Fossella FV; Glisson BS; Lee JS; Murphy WK; Shin DM; Kemp BL; Lee JJ; Kane J; Robinson RA; Lippman SM; Kurie JM; Huber MH; Raber MN; Hong WK
    J Clin Oncol; 1996 Feb; 14(2):503-13. PubMed ID: 8636764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
    Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
    J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of rubitecan in recurrent or metastatic head and neck cancer.
    Caponigro F; Cartenì G; Droz JP; Milano A; Davis WB; Pollard P
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):209-14. PubMed ID: 17882418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
    Scher RM; Kosierowski R; Lusch C; Alexander R; Fox S; Redei I; Green F; Raskay B; Amfoh K; Engstrom PF; O'Dwyer PJ
    Invest New Drugs; 1996; 13(4):347-54. PubMed ID: 8824355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer.
    Lad T; Rosen F; Sciortino D; Brockstein B; Keubler JP; Arietta R; Vokes E
    Invest New Drugs; 2000 Aug; 18(3):261-3. PubMed ID: 10958595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. A Southwest Oncology Group trial.
    Taylor SA; Benedetti J; Schuller D; Richman SP; Broun GO; Hantel A
    Invest New Drugs; 1993; 11(2-3):227-9. PubMed ID: 8262737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
    Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
    Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck.
    Abele R; Kaplan E; Grossenbacher R; Schmid HJ; Cavalli F
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):333-6. PubMed ID: 6231185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of topotecan in malignant melanoma.
    Kraut EH; Walker MJ; Staubus A; Gochnour D; Balcerzak SP
    Cancer Invest; 1997; 15(4):318-20. PubMed ID: 9246152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of topotecan in patients with previously untreated pancreatic cancer.
    O'Reilly S; Donehower RC; Rowinsky EK; Ord S; Grochow LB
    Anticancer Drugs; 1996 Jun; 7(4):410-4. PubMed ID: 8826609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
    Hudes GR; Kosierowski R; Greenberg R; Ramsey HE; Fox SC; Ozols RF; McAleer CA; Giantonio BJ
    Invest New Drugs; 1995; 13(3):235-40. PubMed ID: 8729952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
    Gilbert J; Cmelak A; Shyr Y; Netterville J; Burkey BB; Sinard RJ; Yarbrough WG; Chung CH; Aulino JM; Murphy BA
    Cancer; 2008 Jul; 113(1):186-92. PubMed ID: 18484593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.